Nov. 04, 2019

BioVersys Receives CARB-X Award of up to US$ 8.92 Million

CARB-X funds BioVersys up to US$ 8.92 million to support the development of first-in-class anti-virulence small molecule drugs that disarm bacteria, opening the door for a paradigm shift in AMR therapy.

Article here